



## IHH Healthcare Berhad

### **DR TAN SEE LENG TO RETIRE AS MANAGING DIRECTOR AND CEO AT IHH HEALTHCARE; TO BE SUCCEDED BY DR KELVIN LOH**

**Kuala Lumpur, May 27, 2019** – IHH Healthcare Berhad (“IHH” or the “Group”) today announced that its Managing Director and CEO, Dr Tan See Leng, has elected to retire upon the completion of his contract period on 31 December 2019. The Board of Directors of IHH Healthcare has accepted Dr Tan’s request and he will be succeeded by Dr Kelvin Loh, effective 1 January 2020.

#### **Dr Tan’s storied career at IHH**

Dr Tan was appointed Managing Director and CEO of IHH Healthcare on 1 January 2014. He had a distinguished 15-year career in the company, with a series of senior leadership roles including as CEO at Parkway Holdings Limited and then as CEO and MD at Parkway Pantai Limited. Under his leadership, IHH Healthcare has successfully transformed into a major international healthcare company with significant presence in Malaysia, Singapore, Turkey, India through the acquisition of Fortis Healthcare, and a growing footprint in Mainland China and Hong Kong. Under Dr Tan’s leadership, IHH Healthcare has also been focusing on innovation in medical technology.

Dr Tan led the successful dual listing of IHH in 2012, which made the world’s third largest Initial Public Offering (IPO) that year. Since its IPO, IHH Healthcare has delivered stellar financial performance with strong growth in earnings and cash flows. The acquisitions and new projects undertaken by IHH Healthcare in recent years, in very attractive geographical markets, provide a strong base for future growth.

#### **Dr Kelvin Loh to rejoin IHH as Managing Director and CEO**

The Board of IHH is pleased to announce Dr Kelvin Loh<sup>1</sup> as the new Managing Director and CEO of IHH Healthcare. He rejoins IHH from Columbia Asia where he was CEO since 2017. Dr Loh held several senior management positions at IHH Group previously, and last helmed the position of CEO of Parkway Pantai’s Singapore Operations Division, before his move to Columbia Asia. Dr Loh joined the IHH Group in 2008 after a decade in the public sector and was a practicing physician prior to that. His appointment follows an extensive global search by an independent international recruitment agency.

---

<sup>1</sup> Please see CV in appendix for additional details

Dr Tan will be working closely with the Board of Directors and senior management at IHH to ensure a seamless transition to Dr Loh's leadership.

***IHH Chairman, Dato' Mohammed Azlan bin Hashim, said:*** "On behalf of the Board, I would like to acknowledge See Leng's immense contributions to building IHH. Under his stewardship, the Group has grown to become a leading global healthcare provider with a footprint of 83 hospitals across 12 countries. His passion and commitment to the business have been exemplary.

"At the same time, we are delighted to welcome Kelvin back to the Group. Kelvin has relevant experience having managed IHH hospitals in Singapore, and Columbia Asia hospitals in IHH's home markets of Malaysia and India. We believe he is exactly the right person to take IHH forward to even greater success while maintaining the core values and attributes of the Group."

***IHH Managing Director and Chief Executive Officer, Dr Tan See Leng, said:*** "I am grateful and humbled for the opportunity to lead IHH's development and work with an extraordinary team during my time here. Together, we have achieved significant progress and growth on behalf of our stakeholders.

"Having laid the groundwork for the next phase of IHH's journey, it is an opportune time to pass the baton. I look forward to ensuring a seamless transition for the business."

***Incoming IHH Managing Director and Chief Executive Officer, Dr Kelvin Loh, said:*** "I am excited and honoured by this appointment and look forward to working with the many experienced leaders and partners across IHH's global platform. I worked with Dr Tan for a number of years and had the privilege of having him as my mentor. I look forward to building on Dr Tan's strong legacy at the IHH Group."

Dr Loh will join IHH as the CEO-designate and Executive Director on 1 July 2019.

*For further information or to speak to an IHH spokesperson, please contact:*

Penelope Koh  
t. +65 6307 7881  
e. [penelope.koh@ihhhealthcare.com](mailto:penelope.koh@ihhhealthcare.com)

Josephine Chew  
t. +65 9061 0353  
e. [jchew@we-watatawa.com](mailto:jchew@we-watatawa.com)

Janet Low  
t. +65 6349 5764  
e. [janet.low@ihhhealthcare.com](mailto:janet.low@ihhhealthcare.com)

**About IHH Healthcare Berhad (“IHH”)**

IHH Healthcare Berhad is a leading premium integrated healthcare provider in markets where the demand for quality care is strong and growing. We are one of the largest healthcare groups in the world by market capitalisation and are listed on the Main Market of Bursa Malaysia and the Main Board of SGX-ST.

Employing more than 55,000 people and operating over 15,000 licensed beds across 83 hospitals in 12 countries worldwide, the Group offers the full spectrum of integrated healthcare services from clinics to hospitals to quaternary care and a wide range of ancillary services across our three operating subsidiaries:

- **Parkway Pantai Limited** is one of Asia's largest integrated private healthcare groups with a network of 29 hospitals throughout the region, including Malaysia, Singapore, India, China, Brunei and UAE. Its “Mount Elizabeth”, “Gleneagles”, “Parkway” and “Pantai” brands are among the most prestigious in Asia.
- **Acibadem Holdings** is Turkey’s leading private healthcare provider, offering integrated healthcare services across 22 hospitals in Turkey, Macedonia, Bulgaria and Amsterdam. The “Acibadem” brand is renowned for its clinical excellence in the Central & Eastern Europe, Middle East and North Africa (“CEEMENA”) region.
- **Fortis Healthcare Limited** is a leading integrated private healthcare provider in India. It operates across a network of 32 healthcare facilities and 378 diagnostic centres in India, Dubai, Mauritius and Sri Lanka. Fortis is listed on the Bombay Stock Exchange.
- **IMU Health** is IHH’s medical education arm, and oversees the established higher learning institutions of International Medical College (“IMC”) and International Medical University (“IMU”) in Malaysia.

IHH is the leading player in our home markets of Malaysia, Singapore, Turkey and India, and key growth markets of China and Hong Kong. For more information, please visit [www.ihhealthcare.com](http://www.ihhealthcare.com).

**APPENDIX**

**CV – Dr Kelvin Loh, MBBS, MBA**

**Dr Kelvin Loh, 45**



Dr Kelvin Loh joins IHH from Columbia Asia Group where he was Chief Executive Officer (“CEO”). Dr Kelvin Loh started his career as a practicing physician before serving for 10 years in the public sector in Singapore, in areas such as clinical services development, hospital planning and hospital operations.

Dr Kelvin Loh previously joined the IHH Group in 2008. Between 2008 and 2017, he held a number of senior management roles before taking over as CEO for Singapore Operations Division covering among other services, the 4 multi-specialty tertiary hospitals – Mount Elizabeth, Mount Elizabeth Novena, Gleneagles and Parkway East.

Dr Kelvin Loh moved to Columbia Asia Group as CEO in 2017 where he was responsible for overseeing Columbia Asia Group’s 28 hospitals across 4 countries in Asia including Malaysia and India.

Dr Kelvin Loh is a senior healthcare executive with strong track record of delivery. He has extensive experience in leading large healthcare businesses, building relationships with stakeholders, managing hospital operations, financial management and developing people. He is also deeply familiar with the healthcare operating context in diverse countries across Asia.

Dr Loh holds a Bachelor of Medicine and Bachelor of Surgery and a Master of Business Administration from the National University of Singapore.